OXi4503 combretastatin A1 di-phosphate: Phase Ib/II started

OxiGene began an open-label, U.S. Phase Ib/II trial to evaluate OXi4503 as a single agent and in combination with intermediate-dose cytarabine. The dose-escalation Phase Ib portion will enroll up to 2...